Current Studies

To apply online for any of our studies, click here.

SL1506-001: One time blood draw for patients who have a viral load equal or greater than 20.

SL1506-001: One time blood draw for patients with Hepatitis.

SL1506-001: One time blood draw for pregnant women that are known to be HIV positive or from pregnant women that are  at high risk for HIV exposure.

S-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Primary Objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of GS-9620 in HIV-1 infected controller on antiretroviral treatment and during analytical treatment interruption following GS-9620 dosing. 

Some of the inclusions:

  • HIV-1 infected subjects of >18 years at Pre-Baseline/Day -13.
  • Pre-antiretroviral therapy with viral load between 50 and 5,000 copies/ml.

Some of the exclusions:

  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 90 days prior to screening.
  • Chronic hepatitis B infection.
  • Hepatitis C antibody positive.

Some potential risks include:

  • Transient flu-like symptoms (such as chills and fever).
  • Transient increases in plasma HIV-1 viral load that are expected to resolve by the end of the dosing period.

GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/emtricitabine/Tenofovir Alafenamide in HIV-1 infected Subjects who are Virologically Suppressed.

Some of the inclusions are:

  • At least 18 years of age.
  • Currently receiving an antiretroviral regimen of DTG+F/TAF or DTG+F/TDF for at least 3 months.

Some of the risks include:

  • Diarrhea, Headache, Nausea, Fatigue, Joint pain, Back pain.

ViiV 204862-Tango: A Phase 3, randomized, multicenter, parallel-group noninferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed.

Some of the inclusions:

  • At least 18 years of age.
  • HIV-1 infected men or women.

Some of the exclusions:

  • Women who are breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of an active CDC  stage 3 disease.
  • Unstable liver disease, Hep B or Hep C.

ARLG_Pnaat-Yr3 (Swab Study): Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Extragenital Sites.

Primary Study Objective:

  • Neisseria gonorrhoeae in rectal swabs
  • Neisseria gonorrhoeae in throat swabs
  • Chlamydia trachomatis in rectal swabs
  • Chlamydia trachomatis in throat swabs

Study Population: Patients present for STD testing for Neisseria gonorrhoeae and Chlamydia trachomatis.